Skip to main content

Table 1 Serious toxicities after re-irradiation with stereotactic body radiotherapy for lung tumors in patients previously treated with thoracic radiotherapy

From: Serious gastric perforation after second stereotactic body radiotherapy for peripheral lung cancer that recurred after initial stereotactic body radiotherapy: a case report

Authors and Reference number Number of patients Tumor location (central/peripheral) Initial irradiation dosea Re-SBRT dosea Non-lung toxicities of grade 4–5 (tumor location) Lung toxicities of grade 4–5
Peulen et al. [4] 29 11/21 30 Gy/2 Fr
40 Gy/4 Fr
30 Gy/2 Fr
40 Gy/5 Fr
G5 hemoptysis: 3 pts (central)
G4 othersb: 2 pts (central)
None
Liu et al. [6] 72 4/68 63 Gy/Conv 50 Gy/4 Fr NA G5 pneumonitis: 1 pt
Reyngold et al. [7] 39 NA 61 Gy/Conv 70.4 Gy (BED10) G4 skin: 1 ptc (peripheral) None
Kilburn et al. [10] 33 17/16 66 Gy/33 Fr
50 Gy/5 Fr
50 Gy/10 Fr G5 aorta-esophageal fistula:
1 pt (central)
None
Trovo et al. [11] 17 17/0 50–60 Gy/20–30 Fr 30 Gy/5–6 Fr G5 hemoptysis: 1 pt (central) G5 pneumonitis: 1 pt
Parks et al. [17] 27 18/11 64.8 Gy/Conv 50 Gy/5 Fr G4 chest wall pain: 1 pt None
  1. Abbreviations: BED 10 biologically effective dose (α/β = 10), Conv conventional fractionation, Fr fractions, G grade, NA not available, pt patient, Re-SBRT re-irradiation with stereotactic body radiotherapy
  2. aMedian dose or frequently used dose
  3. bVena cava superior stenosis and fistula between the trachea and gastric tube developed in a case with a recurrent tumor at the carina
  4. cSBRT was performed for a right lung tumor in a patient who had received contralateral lung irradiation [19]